(Esophageal Cancer) Is Zanidatamab + Chemotherapy Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- February 9, 2023
- Reading time: 1 minute
On January 19, 2023, Jazz Pharmaceuticals and Zymeworks announced initial analysis results from a Phase II clinical trial evaluating zanidatamab plus chemotherapy as first-line treatment in HER2-positive metastatic gastroesophageal adenocarcinoma patients.
This Phase II trial enrolled HER2-positive metastatic gastroesophageal adenocarcinoma patients (N=42) and administered zanidatamab plus chemotherapy as first-line treatment. Evaluation endpoints included overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
Initial Analysis Results at Median Follow-up of 26.5 Months:
- Median OS: not reached
- 18-month OS rate: 84%
- 12-month OS rate: 88%
- Objective response rate: 79%
- Disease control rate: 92%
- Median duration of response: 20.4 months
- Median progression-free survival: 12.5 months
Safety:
Adverse events observed in this trial were consistent with those seen in prior clinical trials and were within manageable range.
Based on these initial analysis results, lead investigator Dr. Elena Elimova of Princess Margaret Cancer Centre stated that gastroesophageal adenocarcinoma carries a high cancer mortality rate, and compared with OS data from previous clinical trials, zanidatamab plus chemotherapy demonstrated exceptionally favorable outcomes in this trial.
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4